GSK gets an entry in the list with Exdensur (depemokimab), a twice-yearly injectable IL-5 inhibitor for severe asthma, which ...

The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...

Welcome, everyone, to the JPMorgan Healthcare Conference. We are pleased to have with us the Almirall management team here with us today, Carlos Gallardo, Chairman and CEO; Karl Ziegelbauer, CFO; Jon ...

In the slopocalypse of 2026, there’s a lot of fake news floating around about diet. Those talk-to-camera videos of shirtless ...

A new study published in Otolaryngology–Head and Neck Surgery reveals that glucagon-like peptide-1 receptor agonists ...

What starts as a minor inconvenience can snowball into chronic sinusitis, recurrent infections, and even more serious ENT ...

A new Australian study has found that a simple saline nasal spray could help many children breathe and sleep better, ...

Treatments for are allergic fungal rhinosinusitis, bipolar I disorder, Hunter syndrome, Leber hereditary optic neuropathy, ovarian cancer, and schizophrenia under review.

Explore innovative strategies for team-based care, emphasizing collaboration among diverse healthcare professionals to ...

Panelists discuss how identifying candidates for anti-amyloid therapy requires precise evaluation of disease stage, cognitive ...

RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.

Randomized trial shows resolution of about half of cases, on par with intranasal steroids ...